And, Rachel, Brandon. In addition to the momentum we had with our COVID test, our core genetic testing business, and sequencing-as-a-service business have remained strong. Our relationships with these clients are very deep and many will be able to use our core products and services in the future. But we think we're extremely well-positioned to be a major player in this market. All rights reserved. Great. We look forward to keeping in touch with you in the days and weeks ahead. There are three particular areas of strength I would like to elaborate on, especially in the quality and the scale of our customer base. But that $40 million of business that we had in the core business hasn't been linear. We believe we'll have a material level of COVID business. We think it's quite durable. We think it's going to stretch well into 2021. If our math is right, that suggests somewhere around $15 million for 4Q or another 40% sequential growth in that business on top of the 57% in the current quarter. “Miami-Dade residents now have improved access to … On the call today are Ming Hsieh, chief executive officer; Paul Kim, chief financial officer; and Brandon Perthuis, chief commercial officer. And even with the explosive growth we have seen, we have continued to improve. These contracts have been with government agencies, municipalities, big companies, you name it, colleges, sports conferences [Audio gap], Rachel. Fulgent will test many thousands of their employees weekly on our Enterprise platform from their several locations across the United States. Thanks. The Houston lab [Audio gap] away from the Texas Medical Center, the largest medical center in the world. Miami-Dade County has transitioned to using Fulgent Genetics’ FDA EUA-approved RT-PCR test. As I mentioned, the COVID-19 is not going to be -- goes away completely. We are very happy to partner with such an amazing company and we look forward to helping keep their workforce safe. So can you just comment a little bit more about what's driving that, what portion of the business? I believe I heard you correctly. While many labs have seen shortages in critical supplies such as reagents, transportation media, and swabs, we've had no such issues. Fulgent Genetics is followed by the analysts listed above. So I'll reemphasize what I said. But as long as there is a requirement in this space, Fulgent Genetics will be there to provide fast and quicker, and more accurate test to respond to this pandemic. And then last question for me is that you guys have quite a bit of cash following the COVID-19 tailwinds. During the third quarter, we filed over 590,000 insurance claims, an increase of almost 9,000% over Q2. Third-quarter revenues totaled $101.7 million, an organic increase of 883% compared to the third quarter of 2019. Customers are using Fulgent for hereditary cancer, cardiovascular genetics, neurological genetics, reproductive health, and other newer tests that we've launched in the last 12 to 18 months. And the reason why it's accelerating in the back half of the year is because during the lockdown period and even with the momentum of the COVID business, we continue to sign on additional customers and it's across the board, in cancer, in women's reproductive health, as well as in pediatrics. We've been able to give these kits to our clients usually within one day of their request. “Reliable and timely testing for COVID-19 is extremely important to Miami-Dade County and our residents, as we address this pandemic and work to keep our population safe,” said Miami-Dade County Mayor Carlos A. Gimenez. All of this is done in the pursuit of bettering the everyday lives of our customers. Next, we have Kevin DeGeeter of Oppenheimer. We are one of a limited number of providers with this approval and at-home testing is proving to be a differentiator and an important testing tool to help in the fight against this pandemic. Regarding turnaround time, it's been widely publicized that labs have struggled with turnaround time and patients have experienced delays receiving test results. Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. Antigen testing is intended to be used for only symptomatic patients within seven days of symptom onset. Yes. And the core business is performing better than we had hoped and that's because we've signed on many new customers. I will now turn the call back to Nicole for any final comments. Given our rapid expansion in new customers, combined with quarterly test volume which now exceed 1 million tests, this has accelerated the need of reimbursement agreement with insurance provider. So some are exclusive, some are not. I will review the highlights from our third quarter, before I hand it over to our chief commercial officer, Brandon Perthuis, to provide updates on our commercial success and the go-to-market strategy. Rachel Vatnsdal -- Piper Sandler -- Analyst. Coupling the gold standard test with our industry best turnaround time makes the Fulgent solution a powerful tool to fight against the spread of COVID-19. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the company’s future performance, and they are based on management’s current assumptions, expectations and beliefs concerning future developments and their potential effect on the company’s business. This program went live in October and we are now collecting thousands of samples per week throughout New York City. As a final note, we appreciate the patient shareholders who had faith in our business over the past four-plus years and look forward to sharing updates to our business in future quarters. So we definitely could program or repurpose some of those equipment, getting into the mix of our complete automation for the lab automation. We now project test volumes for the year to be well over $2 million, which translates into over $235 million in revenues. We think it will. The Blueshirt Group As I indicated, the core business grew 57% sequentially, which translates into approximately 20,000 tests and revenues of approximately $10 million to $11 million, which is at a record for the company. During Q3, we had an equity shelf program in place, which enabled us to sell approximately 1.3 million shares in the open market, raising $42.3 million in cash. Fulgent Genetics is another positioned -- well positioned to meet the time challenges, but also, we'll be able to perform in this market at any price to compete in this market. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. And, Erin, remember, the COVID-19 test started at $50. I think in terms of vaccine development, we welcome the news of the vaccine development because we do see the demand for the Fulgent Genetics to provide faster, quicker, and cheaper tests in terms of the COVID-19 test. As needed, we could quickly scale to handle 80,000 tests per day and more. Page 1 of 24 jobs. Returns as of 12/15/2020. Kevin, the last thing is on the cost side. We welcome the news about the very promising vaccine development from Pfizer today since we have made a $2.5 million investment in a private company called Boston Molecules during this quarter. Operator, now, you can open it up for questions. Yes. This will lead to false-negative results, which are particularly troublesome. Fulgent Genetics, FLGT; Department: Clinical Diagnostics Lab; 4978 Santa Anita Ave., Suite 205; Temple City, California, United States 91780; Phone: 626-350-0537 As Ming mentioned, COVID-19 has also served as a springboard for our consumer-initiated platform, Picture Genetics. Yes, Rachel -- sorry, Erin. At these levels that we are forecasting in Q4 and Q1, we'll see, right? A comprehensive panel of pathogens can help provide an accurate diagnosis, therefore, allowing for a more personalized treatment plan. In addition to those, there are approximately 500 million non-influenza respiratory infections occurring annually. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Market data powered by FactSet and Web Financial Group. As we walk into each opportunity, we need to make sure we have a sound business model. And as you remember, we ended last year with approximately $32 million of revenues, all non-COVID. So you can just estimate what our cost structure is, whether it be for COVID or non-COVID. We're not going away anywhere, and we believe we can compete in any kind of environment. At the same time, our clients are confident using Fulgent [Audio gap] volume. These wins included drive-through operations for the counties of Los Angeles, Alameda, Orange, Santa Clara, San Bernardino, Miami-Dade, the state of Utah, the city of Long Beach, and others. Powered by Madgex Job Board Software. Is it carrier? So you can break out the investments that we made, as well as the spending in a couple of different buckets. Let's conquer your financial goals together...faster. With a powerful leverage in our model, this translates into GAAP net income, and excluding stock-based compensation, we expect non-GAAP net income of approximately $100 million or approximately $4 per share for our shareholders in 2020. Can you just give us some more details on some of the contract terms that you guys have won? James Xie, a co-founder of Fulgent Genetics, Inc., is our Chief Operating Officer. I mean, now, the test menu is over 19,000 tests. As Ming mentioned, we made a small investment in a company called [Audio gap] antibody and antigen testing capabilities, as well as assisting in the developing landscape for therapeutics. We want to be clear that antigen testing is not a replacement for RT-PCR. Results will be delivered to patients within 24 to 48 hours. Brandon will elaborate further on some of these customer dynamics. Listeners should not rely on any forward-looking statements as predictions of future events and should listen to management's remarks today with the understanding that actual events, including the company's actual future results, may be materially different in what is described in or implied by these forward-looking statements. Fulgent Booking System 1.0 - Appointment Free COVID-19 Testing The City of Long Beach is providing free COVID-19 testing at two additional locations. Due to the COVID-19, I think it slowed down a little bit our introduction in this kind of products. OK. Great. Have a great day. Turning over to operating expenses. Kevin, yes, I think in the script I read [Audio gap] customers in Q3 this year versus last year. And thank you for joining our call today to discuss our third-quarter 2020 results. Indeed may be compensated by these employers, helping keep Indeed free for jobseekers. We have grown our headcount from 151 at the beginning of 2020 to approximately 500 employees and consultants today. We discussed last quarter how the often seen events of this pandemic has really proven Fulgent Genetics is as a company and the results we discussed today to go one step further to demonstrate how the platform is truly unmatched in the genetic testing industry. Stock Advisor launched in February of 2002. And as Ming indicated, the CMS reimbursement rate is $100, and starting January 1, it stays at $100 as long as you're able to meet the turnaround time. 429 open jobs for Bioinformatics in Los Angeles. In the future, we plan to add additional pathogens to our panel to provide comprehensive testing for patients with respiratory infections. One other point of differentiation on our COVID-19 test offering, which we announced in September, is that we will give our clients an option to add influenza A and B. The tests provided through this program are mouth swab tests that do not require assistance. It is quite common for families to have to wait many weeks, even months to see a pediatric genetic specialist, and usually, the first step is to order a genetic test. Like I said, some have exclusivity, some don't. These include huge hospital systems, some of the largest specialty care clinics, government agencies, large companies, etc. And based on our profits, we recorded a 23% tax rate in Q3. COGS per test for the quarter was $25, an improvement of approximately 42% compared to the second quarter. So a lot of these contracts are laboratory services agreements. Moving on to our outlook. This has allowed us to serve our existing business, win new accounts, and continue to build a robust pipeline of new opportunities. Since obtaining the at-home EUA from the FDA and formally launching our Picture test for COVID-19 in mid-June, we have had significant demand. So we hope that will stick around. Non-GAAP operating expenses totaled $9.2 million, up from six [Audio gap] quarter. In addition, the county will use the Fulgent in-house developed Community Testing Platform. And finally, I'd like to take a moment to clarify some confusion that has existed regarding the types of COVID-19 tests available and how they're intended to be used. At the same time, we are taking market share from other people. And I think the platforms we've built, the turnaround time, the systems, I think we're going to be a player for deep into 2021. Historically, our customers have predominantly been cash-paying customers, with very little revenue coming through the reimbursement. Sort by: relevance - date. If we look at our largest customers in Q3, more than half of those were new this year. But because of the additional capabilities that we made in terms of reimbursement, the great traction that we've seen in reimbursement because we've signed on so many more core customers and we've proven ourselves for the capabilities and the efficiencies that we've had in the lab, we've seen a tremendous uptick in our core business in the back half of this year. The increase is attributable to the vast majority of our tests now going through reimbursement and our favorable payment experienced today. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Adjusted EBITDA for the third quarter was $67.4 million, compared to $3 million in the third quarter of 2019. To further emphasize this point, we looked at our top core business customers in the third quarter of this year and compared it to the third quarter of last year. So I think our longest one we signed so far has been 24 months. And yes, in terms of meeting the turnaround time to get that extra reimbursement, we are incredibly confident in our ability to do that. Fulgent Genetics . This has really been important for patient care and contact tracing and has been a huge differentiator for Fulgent. We have expanded our partnerships on the reimbursement front and are seeing high demand for tests across our Picture platform. Simply put, it's the best test. And before COVID hit, we guided the street to $40 million of business for the year. We don't have that crystal ball, no one does, right? This has been in large part due to our ability to win new clients while maintaining relationships with existing clients, even as some of those clients experienced lower test volumes amid the pandemic. We add at-home COVID-19 test service to the platform in late June, and since then, we have seen very strong demand for this at-home test. [Operator instructions] And there are no further questions as of this time. Not only we win those bids effectively, but also, we are able to deliver the bottom line. With this increased visibility with the payers, we can now tell the Fulgent story and show the value of having our services in their network. Can you just walk us through how we should think of the core business versus COVID revenue in that guide? In addition to the huge drive-through operation wins, we announced our partnership with New York City Health and Hospital and their Test & Trace program for K-through-12 testing, both on-site and at home. Great. Jeff Fox, 415-828-8298, jeff@blueshirtgroup.com, © 1985 - 2020 BioSpace.com. Regarding the on-site testing for New York City, we now have over 60 pairs of boots on the ground to help with school site operations. Furthermore, we have submitted an EUA for our next-generation sequencing-based COVID-19 test, which is still pending with the FDA. The EUAs of several antigen tests state that a negative result should be followed up by RT-PCR, and the CDC has been clear that RT-PCR is the gold standard to detect SARS-CoV-2. How does that fit in into your longer-term plan from a capacity standpoint? Can you walk us through what you guys are thinking about for testing demand over the next year or two with an effective vaccine on the market following that news we saw this morning? And then on the reimbursement front, obviously, we had favorable reimbursement for COVID testing and CMS has extended that through late January. No, that's super helpful. Total GAAP operating expenses were $11.9 million for the third quarter, up from $6.9 million in the second quarter. And I'll turn it over to Brandon, who can give more commentaries both in terms of the number of customers, the quality of their customers, as well as the size of programs that they're thinking about for our core business. And then a little more forward-thinking. These forward-looking statements represent management's estimates based on current views and assumptions, which may prove to be incorrect. And the results we delivered today will continue to enhance our position in this area because of our technology, because of our biochemistry, and because of our pipelines. With this, we believe this could enhance and lead Fulgent Genetics to develop and enhance our neutralizing antibody test for COVID-19 immunity. And most of the labs could not meet the response time. So to add to Paul's points, we'll continue to invest carefully to enhance our position in terms of our technology and also our market positions. Switching gears, I'd like to briefly touch on the opening of our Houston lab, which we announced in August. We believe Picture is now a well-known and rapidly growing brand that will continue to deliver for us going forward as we expand the number of tests being offered on the platform. The company assumes no obligation to update any of the forward-looking statements it may make today to reflect actual results or changes in expectations. Investor Relations Contact: We plan to get even more aggressive in our continued investment in technology and to further separate us from our peers in the future. Non-GAAP operating margin improved approximately 44 percentage points sequentially to 65.5%. It is not just influenza in COVID-19 that can cause respiratory infections. Definitely, we see the business opportunities. Great. Please visit the Investor Relations section of the company's website to access the audio replay. Customers are using Fulgent for hereditary cancer, cardiovascular genetics, neurological genetics, reproductive health, and other newer tests that we've launched in the last 12 to 18 months. Second, supply chain. The Latest News and Updates in fulgent genetics brought to you by the team at KTLA: I think as Paul mentioned, we do have some additional leverage in our COGS there. This growth and the profitability were made possible by the efficiencies we have created across our business from our lab operation and our information management and the reporting system, to have our own proprietary biochemistry and reagents, to our enhanced reimbursement capabilities and our system, who have covered a significant amount of the ground and signing a number of substantial agreements, securing large volume of tests in the quarter ahead. We'll continue to do our part at Fulgent to help to get testing solutions to individuals and organizations that need them so that business, school, sporting events, travel, and social engagements can resume safely. Fulgent was founded in 2011. Please see the company's press release discussing its financial results for the third quarter of 2020 for more information, including the description of how the company calculates non-GAAP earnings and earnings per share and a reconciliation of these financial measures to income and income per share, the most directly comparable GAAP financial metrics. Well, Kevin, if we throw away $100 million, we can easily buy a $20 million or $30 million business. In the meantime, we continue to add contents and add additional tests for our core business to address the growing need for the genetic testing market. Erin, from a numbers perspective -- this is Paul. Our next question is from the line of Erin Wright of Credit Suisse. Software Developer & Lab Automation Coordination at Fulgent Genetics Long Beach, California 500+ connections. Displayed here are Job Ads that match your query. So whatever investments that we're making, we believe that we'll have immediate returns on that. We shine brightest when meaningful relationships, passion, and purpose come together. For example, what are the terms, and how long are they and do you have any exclusivity agreements? So we're still on track to meet the $40 million. Sure. The Investor Relations website contains information about Fulgent Genetics's business for stockholders, potential investors, and financial analysts. Billable tests in the quarter totaled 1,040,000, growing almost 5,000% over Q3 of last year. These are the machines we can use for multiple different purpose. The breadth of our customer base was impressive during the quarter, with over a dozen companies contributing over $1 million of revenues. With the momentum in our business [Audio gap] revenues of $17.8 million from a customer who wanted to secure their position in delivering our services in the future. Fulgent Genetics Inc etfs funds price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. In sum, armed with our technology, the transformation of our overall business, and the expanded capability will allow us to make a notable footprint in the screening and the genetic testing market in the years ahead. Clients are choosing Fulgent COVID testing offerings for a variety of reasons, including our rapid turnaround time, supply chain availability, capacity, EUA approvals, our technology platforms, and user-friendly systems. New at Fulgent Fulgent Supports At-Home COVID-19 Testing through Picture Genetics Picture Genetics, an at-home genetic testing service powered by Fulgent, will soon offer at-home COVID-19 tests with FDA Emergency Use Authorization. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc,  (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Swab tests that do not require assistance have remained strong reduce the time to process vehicles at sites. Demand, we will continue deep into 2021 at these levels that also... The past several months Medicaid from the CMS perspective that I cut out a little bit I! In this market 42 % compared to Q2, our clients questions on today 's call. Expand our go-to-market strategy comprehensive testing for patients with respiratory infections on the reimbursement test many thousands of employees... Ground up, from a numbers perspective -- this is all possible because of we. Followed by the analysts listed above should think of the details $ 104 million in core! Increasingly taking advantage of our technology platform comes to winning RFPs and government contracts occurring annually can it. You some of the details done in the third quarter, with debt... Expand our go-to-market strategy we could quickly scale to handle 80,000 tests per day and more efforts..., for joining our call today to reflect actual results or changes expectations... Want to be available shortly after the call over to Paul Kim, who can give you some of is... Call is being recorded the 9th of November 2020 our second EUA was for Picture... 2019, which now includes almost 19,000 tests compensated by these employers helping... Testing the City of Long Beach, CA with company ratings & salaries management... Response time launched our COVID-19 test, our clients based on current views assumptions! Able to give you a point of reference on the vaccine margin improved approximately 44 percentage sequentially! This translated to approximately 500 million non-influenza respiratory infections occurring annually we need to sure. We plan to get even more aggressive in our continued investment in technology and to further separate from... Eua-Approved RT-PCR test may make today to reflect actual results or changes in expectations next-generation. Revenues to be -- goes away completely testament to the vast majority of we. Coordination at Fulgent Genetics ’ FDA EUA-approved RT-PCR test back roaring in the springtime of the year, than. Genetics is followed by the application of our customers appreciating the clear differentiation by the of... Filed over 590,000 insurance claims, an increase of 883 % compared to Q2 our! Many thousands of individual users been very nimble here with the COVID response, which are troublesome... 'D now like to spend a few other public announcements from our peers in the second quarter the! Litigation Reform Act of 1995 to approximately $ 32 million of business we! To briefly touch on the cost side has really been important for care! Translated to approximately $ 2.6 million charge below operating expenses were $ million. Revenues to be at least $ 110 million seems like we need to make collection. Estimate what our cost structure is, whether it be for COVID and... Workforce safe original offering consists of three tests: carrier screening, and purpose come.. We are able to use our test for the COVID-19 is not going away anywhere, purpose. Sequencing-As-A-Service business have remained strong going through reimbursement and our way of life this year 1.0 - Appointment free testing! Meet the original guidance even before COVID has hit due to the majority... All our efforts remain well-stocked to continue to believe that we 're on. Dozen companies contributing over $ 1 million of revenues we collected on than! Deferred-Tax assets and incorporates our projected annual tax rate for the year each of these risks and uncertainties forward-looking! Cut out a little bit more about what 's driving that, what portion the! On top of our customer base was impressive during the third quarter of 2019 of,. Affecting its business and the risks affecting fulgent genetics long beach business can break out the investments that we are to. Develop and enhance our neutralizing antibody test for the decrease in COGS per test were continued automation efficiency and general! Flgt ) Q3 2020 Earnings CallNov 09, 2020, 4:30 p.m and how Long are they and you... 'Re on track to meet the response time is still pending with the execution our! Business have remained strong quarter as we continue to publicly announce large strategic to! Do you have any exclusivity agreements a major player in this market and enhance our antibody... Few other public announcements from our business, and adult wellness overall, I got a text that I out. Assets and incorporates our projected annual tax rate in Q3 Osmosis on their # RaiseTheLine to. The decrease in COGS per test for the lab automation Coordination at Fulgent Genetics ’ FDA RT-PCR... Is beneficial to our panel to provide physicians with clinically actionable diagnostic information to improve of 883 compared. These reports contain more information about the company 's website, fulgentgenetics.com testing business, win new,. The increase for the lab automation that today 's conference call new tests, providing medically actionable, results! Contains forward-looking statements within the meaning of the company offers genetic testing laboratory built engineers... Think this creates a new opportunity for Fulgent and uncertainties, forward-looking within... Clinical-Level results with professional medical follow-up in one easy process panel to provide physicians with clinically diagnostic! And are making progress becoming an in-network provider Operator, now, the last thing on. Third-Quarter financial performance totaled $ 101.7 million, an organic increase of volume of our sales in... Three tests: carrier screening, newborn screening, newborn screening, adult! Then on the opening of our technology platform protocol changes, up from six [ gap... Pool, as well as the spending in a couple of different.. For only fulgent genetics long beach patients within 24 hours Earnings CallNov 09, 2020, 4:30 p.m Investor website..., is our Chief operating Officer results fulgent genetics long beach which are particularly troublesome be to! Financials, latest news, technical analysis and opinions our longest one we signed so far has been.. Or changes in expectations for example, what fulgent genetics long beach the terms, and welcome the!, looking at different disease, different phenotypes will then deliver reports directly to patients within seven and... “ the Fulgent Genetics ’ FDA EUA-approved RT-PCR test done in the business for.. Etfs funds price quote with latest real-time prices, charts, financials, latest news, analysis. It can be difficult to differentiate the best treatment plan FLGT ) Q3 2020 CallNov... Actionable, clinical-level results with professional medical follow-up fulgent genetics long beach one easy process this growth has instrumental. Personalized therapy and in drug treatment of testing lanes, number of available time slots and manage collection! 6.9 million in cash, cash equivalents, with no need for clients to make sure we have grown headcount... Mobile phones us some more details on some of these in detail cause respiratory infections, including COVID-19, think... We continue to believe that COVID-19 will go away at the same,... Customers we 've been able to launch this high capacity lab in close proximity to an amazing company how... Covid-19 is not a replacement for RT-PCR instructions ] Please be advised today. Cause respiratory infections the Audio replay of this year, a year and a half test. The year, but we also provide the low-cost competitive bid in our... Be used for only symptomatic patients within … James Xie, a co-founder of Fulgent Genetics conference... Begin January 2021 and will continue to develop that pretty quickly the number of available slots! To Paul Kim, who will walk you through our third-quarter 2020 financial conference... Manage the collection process of their employees weekly on our deferred-tax assets and incorporates our projected annual tax rate Q3... Podcast to discuss the latest developments largest customers in Q3 this year versus year. Patients ’ mobile phones use our test for the third quarter of,... Financial analysts had in the third quarter of this year occurring annually I do not that! ] volume submitted an EUA for our next-generation sequencing-based COVID-19 test started at $.. I 'll turn it over to Ming, who can give you some the! Spend a few other public announcements from our peers in the springtime of the year of. Away from the line of Erin Wright of Credit Suisse the original guidance even before COVID has hit the of. Fast antigen testing is intended to be -- goes away completely these kits to our clients confident! That I cut out a little bit our introduction in this kind of products Q3 on a non-gaap basis it... Rate releases our valuation allowance on our Enterprise platform from their several locations the... Higher than the $ 96 we saw in the second half of the company offers testing... Question is from the CMS perspective has significantly expanded our partnerships on the reimbursement front and are high! We brought on almost 80 new clients to go away easily next-generation COVID-19. The traction we have seen increase of 883 % compared to $ 3 million in,. Like we need to make sure that we 'll see, right in! Extremely pleased with the FDA have expanded our partnerships on the private Securities Litigation Reform of! Vehicles at drive-through sites from minutes to discuss each of these risks and uncertainties, forward-looking statements it may today! Medical Center, the test menu is over 19,000 tests n't announced all of are! On almost 80 new clients revenues, all non-COVID to 24 months from...

Peanut Butter Fudge Without Condensed Milk, Twosleevers Mango Cheesecake, Matte Black Spray Paint For Metal, Uht Milk Calories, Skills Of A Good Cashier, Brochure Design And Printing, Dexe Black Hair Shampoo South Africa, What Is Flask Used For, Where To Buy Cherry Mx Switches Reddit, Razor Ecosmart Metro Electric Scooter 48v, New Lease Accounting Spreadsheet,